<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02424396</url>
  </required_header>
  <id_info>
    <org_study_id>P130102</org_study_id>
    <secondary_id>2014-000088-82</secondary_id>
    <nct_id>NCT02424396</nct_id>
  </id_info>
  <brief_title>Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis</brief_title>
  <acronym>MS-IL2</acronym>
  <official_title>Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis. Multicentric Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation ARSEP/AFM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interleukin-2 (IL-2) was initially discovered and used as a stimulator of effector T&#xD;
      lymphocytes (Teffs), but is now viewed as a very promising immunoregulatory drug having the&#xD;
      capacity to stimulate regulatory T cells (Tregs). At low dose, Il-2 tips the Treg/Teff&#xD;
      balance towards Tregs. Recently, it has been shown that Tregs of MS patients have reduced&#xD;
      proliferative potential. MS-IL2 will assess the safety and biological efficacy of low-dose&#xD;
      IL2 as a Treg inducer in a Relapsing-Remitting Multiple Sclerosis (RRMS), with the aim to&#xD;
      stimulate Treg and define potential clinical benefits&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In MS-IL2, 30 RRMS patients will be treated in a randomized, double-blind, placebo controlled&#xD;
      clinical trial. IL-2 will be administered first as an induction course of IL-2 or placebo&#xD;
      each day for 5 days, followed by a maintenance course at the same dose or placebo every two&#xD;
      weeks over 6 months.&#xD;
&#xD;
      The primary efficacy criteria will be the % change from baseline in Treg at day-5, which is&#xD;
      indicative of the biological response to IL-2.&#xD;
&#xD;
      The secondary efficacy criteria will be (i) the maintenance of regulatory T cells during the&#xD;
      6 months of treatment with IL-2 vs. placebo and (ii) the stabilization or regression of the&#xD;
      disease as determined by disease activity parameters assessed by MRI (cumulative number of&#xD;
      new lesions in T1 enhanced by gadolinium after 6 months) in the groups treated with IL-2&#xD;
      compared to placebo.&#xD;
&#xD;
      Expected impact: MS-IL2 will define which patient respond to IL2 and which doses prevent&#xD;
      relapses in RRMS. In addition, the deep phenomics studies will further provide the foundation&#xD;
      for a clinical phase II to define clinical efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 13, 2016</start_date>
  <completion_date type="Actual">June 15, 2020</completion_date>
  <primary_completion_date type="Actual">October 11, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treg response to low dose IL2 induction course period, expressed as % of total CD4 cells</measure>
    <time_frame>at day5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Treg percentage on D15 after induction (D1-D5) compared to baseline</measure>
    <time_frame>at day15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Treg percentage from D15 to M6 compared to baseline</measure>
    <time_frame>Day 15 to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative number of new lesions enhanced by Gd+ (Sum of Gd + lesions on T1 MRI on M2, M4 and M6)</measure>
    <time_frame>Day 57, Day 113 and Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of patients free of Gd+ lesions at M6</measure>
    <time_frame>Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative number of new T2 lesions</measure>
    <time_frame>Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual relapse rate (number of relapses observed over a 6 month period)</measure>
    <time_frame>Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of patients with flare</measure>
    <time_frame>Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of disease free patient i.e % of patient with no clinical symptoms and no activity on MRI</measure>
    <time_frame>Day 169</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>1 : IL2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interleukin-2 (ILT-101)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 : Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IL2</intervention_name>
    <description>Induction period: repeated administration of low-dose IL-2 Maintenance period: treatment with IL-2</description>
    <arm_group_label>1 : IL2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2 : Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-65 years old ;&#xD;
&#xD;
          -  Male and Female;&#xD;
&#xD;
          -  Presenting relapsing remitting multiple sclerosis as determined by revised McDonald&#xD;
             criteria (2010) ;&#xD;
&#xD;
          -  On MRI : 1) Presenting 1-2 lesions enhanced by gadolinium (Gd+) (T1) without clinical&#xD;
             expression of the disease clinique upon inclusion or 6 months prior to inclusion or 2)&#xD;
             presenting one new lesion T2&#xD;
&#xD;
          -  Expanded Disability Status Scale (EDSS) score comprised between 0 and 6;&#xD;
&#xD;
          -  No flare (with or without any corticosteroid therapy) for the past 2 months&#xD;
&#xD;
          -  Under β-Interferon treatment for ≥ 6 months ; or any other first-line treatment of the&#xD;
             Relapsing-Remitting Multiple Sclerosis (RRMS): Dimethyl fumarate or teriflunomide&#xD;
             treatment for ≥ 6 months or glatiramer acetate for ≥ 9 months&#xD;
&#xD;
          -  For women of childbearing age, contraception for more than 2 weeks upon confirmation&#xD;
             of inclusion criteria and negative Beta HCG on inclusion visit (D-30 to D-7);&#xD;
&#xD;
          -  Patient informed consent should be signed by the patient and investigator before&#xD;
             performing any clinical examination required for the study.&#xD;
&#xD;
          -  Affiliation to the French Social Security Regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Number of lesions enhanced by gadolinium (Gd+) on MRI in T1 &gt; 2 upon inclusion;&#xD;
&#xD;
          -  Known intolerance to IL2 (see SPC):&#xD;
&#xD;
               -  Hypersensibility to active substance or one of the excipients ;&#xD;
&#xD;
               -  Signs of evolving infection requiring treatment&#xD;
&#xD;
               -  Other clinically significant chronic disorders (beside RR-MS)&#xD;
&#xD;
               -  History of organ allograft&#xD;
&#xD;
          -  Administration of a non-authorized treatment; bolus of corticosteroids in the last 2&#xD;
             months, or treatment with cyclophosphamide, mitoxantrone, or rituximab in the last 6&#xD;
             months;&#xD;
&#xD;
          -  Heart failure (≥ grade III NYHA), renal insufficiency, or hepatic insufficiency&#xD;
             (transaminase&gt;5N), or lung failure&#xD;
&#xD;
          -  White blood cell count &lt;3000 /mm3, lymphocytes&lt; 1000 /mm3, platelets &lt;150 000 /mm3&#xD;
&#xD;
          -  Poor venous access not allowing repeated blood tests&#xD;
&#xD;
          -  Vaccination with live attenuated virus in the months preceding the inclusion or&#xD;
             planned during the study&#xD;
&#xD;
          -  Surgery with general anaesthesia during the last 2 months or surgery planned during&#xD;
             the study&#xD;
&#xD;
          -  Participation in other biomedical research in the last one month or planned during the&#xD;
             study&#xD;
&#xD;
          -  Concomitant psychiatric disease or any other chronic illness or drug-abuse that could&#xD;
             interfere with the ability to comply with the protocol or to give informed consent&#xD;
&#xD;
          -  Cancer or history of cancer cured for less than five years (except in situ carcinoma&#xD;
             of the cervix or basocellular carcinoma)&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Men and women of childbearing potential without effective contraception for the&#xD;
             duration of treatment&#xD;
&#xD;
          -  Patients under a measure of legal protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Klatzmann</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre d'investigation Clinique - Pitié salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'investigation clinique Biothérapie Immunologie (CIC-BTi) - Groupe Hospitalier Pitié-Salpêtrière - AP-HP</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Département des maladies du système nerveux et Centre d'investigation clinique - Groupe Hospitalier Pitié-Salpêtrière - AP-HP</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 20, 2015</study_first_submitted>
  <study_first_submitted_qc>April 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2015</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interleukin 2, IL2</keyword>
  <keyword>Relapsing Remitting Multiple Sclerosis</keyword>
  <keyword>Autoimmune diseases</keyword>
  <keyword>Regulatory T cells, Tregs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

